Fresenius Medical Care (FME) Stock Price, News & Analysis

Company Overview

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Key Stats

• Today's Range: €45.91 to €46.91
• 50-Day Range: €46.10 to €53.66
• 52-Week Range: €30.16 to €42.12
• Volume: 480,740 shs
• Average Volume: 704,197 shs
• Market Capitalization: €13.58 billion
• P/E Ratio: 20.61
• Dividend Yield: 2.59%
• Price Target: N/A
• Consensus Rating: N/A

Fresenius Medical Care Stock Analysis - MarketRank™

Fresenius Medical Care scored higher than 81% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Fresenius Medical Care.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Fresenius Medical Care is 20.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.55.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fresenius Medical Care is 20.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.26.

Price to Earnings Growth Ratio

Fresenius Medical Care has a PEG Ratio of 0.42. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Fresenius Medical Care has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for FME.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Fresenius Medical Care pays a meaningful dividend of 2.52%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Fresenius Medical Care does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Fresenius Medical Care is 53.40%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.11

Short Interest

There is no current short interest data available for FME.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: N/A

News Sentiment

Fresenius Medical Care has a news sentiment score of 1.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Fresenius Medical Care this week, compared to 1 article on an average week.

MarketBeat Follows

2 people have added Fresenius Medical Care to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fresenius Medical Care insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.17% of the stock of Fresenius Medical Care is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 38.74% of the stock of Fresenius Medical Care is held by institutions.

FME Stock Analysis - Frequently Asked Questions

How have FME shares performed this year?

Fresenius Medical Care's stock was trading at €44.16 at the beginning of 2025. Since then, FME shares have increased by 4.0% and is now trading at €45.94.

What other stocks do shareholders of Fresenius Medical Care own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fresenius Medical Care investors own include Petra Diamonds (PDL), Fresenius Medical Care AG & Co. KGaA (FMS), Bayer Aktiengesellschaft (BAYN), NVIDIA (NVDA), PayPal (PYPL), Meta Platforms (META) and Micron Technology (MU).

Industry, Sector and Symbol

• Stock Exchange: ETR
• Sector: Medical
• Industry: Medical Care Facilities
• Sub-Industry: Healthcare
• Current Symbol: ETR:FME
• CIK: N/A
• Web: www.freseniusmedicalcare.com
• Phone: +49-6172-6090
• Fax: N/A
• Employees: 113,639
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): €2.23
• Trailing P/E Ratio: 20.61
• Forward P/E Ratio: 13.24
• P/E Growth: 0.42
• Net Income: €663.98 million
• Net Margins: 3.42%
• Pretax Margin: N/A
• Return on Equity: 4.68%
• Return on Assets: 2.90%

Debt

• Debt-to-Equity Ratio: 82.24
• Current Ratio: 1.37
• Quick Ratio: 0.80

Sales & Book Value

• Annual Sales: €19.39 billion
• Price / Sales: 0.70
• Cash Flow: €4.65 per share
• Price / Cash Flow: 9.87
• Book Value: €50.41 per share
• Price / Book: 0.91

Miscellaneous

• Outstanding Shares: 295,670,988
• Free Float: N/A
• Market Cap: €13.58 billion
• Optionable: Not Optionable
• Beta: 0.86